WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H462518
CAS#: 1606974-33-7
Description: Zatolmilast is a phosphodiesterase IV inhibitor.
Hodoodo Cat#: H462518
Name: Zatolmilast
CAS#: 1606974-33-7
Chemical Formula: C21H15ClF3NO2
Exact Mass: 405.07
Molecular Weight: 405.801
Elemental Analysis: C, 62.16; H, 3.73; Cl, 8.74; F, 14.05; N, 3.45; O, 7.89
Synonym: Zatolmilast; BPN14770; BPN-14770; BPN 14770
IUPAC/Chemical Name: (4-{[2-(3-chlorophenyl)-6-(trifluoromethyl)pyridin-4-yl]methyl}phenyl)acetic acid
InChi Key: LTSUMTMGJHPGFX-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H15ClF3NO2/c22-17-3-1-2-16(12-17)18-9-15(10-19(26-18)21(23,24)25)8-13-4-6-14(7-5-13)11-20(27)28/h1-7,9-10,12H,8,11H2,(H,27,28)
SMILES Code: O=C(O)CC1=CC=C(CC2=CC(C3=CC=CC(Cl)=C3)=NC(C(F)(F)F)=C2)C=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 405.80 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: WHO Drug Information, Vol. 34, No. 2, 2020
2: Ricciarelli R, Brullo C, Prickaerts J, et al. Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease. Sci Rep. 2017;7:46320. Published 2017 Apr 12. doi:10.1038/srep46320
3: Gurney ME, Nugent RA, Mo X, et al. Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders. J Med Chem. 2019;62(10):4884-4901. doi:10.1021/acs.jmedchem.9b00193